ERAS
Erasca Inc
NASDAQ: ERAS · HEALTHCARE · BIOTECHNOLOGY
$9.11
-7.98% today
Updated 2026-04-29
Market cap
$6.68B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $24
Volume
6.9M
Erasca Inc (ERAS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $310000.00 | $540000.00 | $829000.00 | $2.64M | $3.73M | $3.81M | $3.11M |
| Gross profit | $-310000.00 | $-540000.00 | $-829000.00 | $-2.64M | $-3.73M | $-3.81M | $-3.11M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $9.62M | $101.30M | $73.92M | $112.46M | $103.82M | $115.36M | $92.85M |
| SG&A | $3.68M | $7.96M | $22.62M | $32.99M | $37.70M | $41.73M | $38.55M |
| Operating income | $-13.29M | $-109.25M | $-124.88M | $-247.45M | $-141.53M | $-179.59M | $-131.41M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-12.98M | $-36.97M | $-121.94M | $-240.16M | $-121.31M | $-153.28M | $-128.30M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-13.29M | $-37.51M | $-122.76M | $-242.81M | $-125.04M | $-157.09M | $-131.41M |
| Interest expense | $0.00 | $336000.00 | $55.86M | $201.36M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-12.04M | $-101.66M | $-122.76M | $-242.81M | $-125.04M | $-161.65M | $-124.55M |
| Net income growth (YoY) | — | -744.4% | -20.8% | -97.8% | +48.5% | -29.3% | +23.0% |
| Profit margin | — | — | — | — | — | — | — |